


DOCKET NO.: BMS-2364/PH-7407NP

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Thais Motria Sielecki-Dzurdz**

**Confirmation No.: Not Yet Assigned**

**Application No.: 10/670,519**

**Group Art Unit: Not Yet Assigned**

**Filing Date: September 26, 2003**

**Examiner: Not Yet Assigned**

**For: PYRIDINO AND PYRIMIDINO PYRAZINONES**

DATE OF DEPOSIT: *December 23, 2003*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

*Elizabeth A. McLoud*

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;  
or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:


- ☒ In view of the voluminous nature of references 12, 14, 22, and 29, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
  - ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ An English language abstract has been provided for reference number 41 which is not in the English language.

Date:

12/23/03

  
S. Maurice Valla  
Registration No. 43,966

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2364/ PH-7407NP	Application No. 10/670,519
	Applicant Thais Motria Sielecki-Dzurdz	
	Filing Date September 26, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
1	Arborelius, L., et al., "The role of corticotrophin-releasing factor in depression and anxiety disorders," <i>J. of Endocrinology</i> , <b>1999</b> , 160, 1-12	
2	Arvanitis, A.G., et al., "Imidazo[4,5-c]pyridines as corticotrophin releasing factor receptor ligands," <i>Bioorg. &amp; Med. Chem. Lett.</i> , <b>2003</b> , 13, 129-131	
3	Boissier, J.R., et al., "A new method for rapid screening of minor tranquillizers in mice," <i>Eur. J. Pharmacol.</i> , <b>1968</b> , 4, 145-151	
4	Boulton, A.J. (Ed.), "The structure, reactions, synthesis, and uses of heterocyclic compounds," <i>Comprehensive Heterocyclic Chemistry II, A review of the Literature 1982-1995, Vol. 6</i> , 120-130	
5	Chalmers, D.T., et al., "Corticotrophin-releasing factor receptors: from molecular biology to drug design," <i>TIPS</i> , <b>1996</b> , 17, 166-173	
6	Chrousos, G.P., "The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes," <i>Int. J. Obesity</i> , <b>2000</b> , 24(Suppl. 2), S50-S55	
7	De Souza, E.B., "CRH defects in alzheimer's and other neurologic diseases," <i>Hosp. Practice</i> , September 15, <b>1988</b> , 59-71	
8	Dunn, A.J., et al., "Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress response?," <i>Brain Research Reviews</i> , <b>1990</b> , 15, 71-100	
9	Funk, D., et al., "Role of catecholamines in the frontal cortex in the modulation of basal and stress-induced autonomic output in rats," <i>Brain Res.</i> , <b>1996</b> , 741, 220-229	
10	Gilligan, P.J., et al., "Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents," <i>J. Medicinal Chem.</i> , May 4, <b>2000</b> , 43(9), 1641-1660	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2364/ PH-7407NP		Application No. 10/670,519
	Applicant Thais Motria Sielecki-Dzurdz		
	Filing Date September 26, 2003	Group Not Yet Assigned	
	Confirmation No. Not Yet Assigned		

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>11</b>	Griebel, G., et al., "Genetic differences in the mouse defense test battery," <i>Aggress. Behav.</i> , <b>1997</b> , 23, 19-31
*	<b>12</b>	Grigoriadis, et al., <i>Biochemical, Pharmacological, and Autoradiographic Methods to Study Corticotropin-Releasing Factor Receptors. Methods in Neurosciences</i> , <b>1991</b> , Vol. 5
	<b>13</b>	Grigoriadis, D.E., et al., "Corticotropin-releasing factor (CRF) receptors in intermediate lobe of the pituitary: biochemical characterization and autoradiographic localization," <i>Peptides</i> , <b>1989</b> , 10, 179-188
*	<b>14</b>	Hawley's Condensed Chemical Dictionary, 13 <sup>th</sup> Ed., R.J. Lewis (Ed.), <i>J. Wiley &amp; Sons, Inc., NY</i> , <b>1997</b>
	<b>15</b>	Heinrichs, S.C., et al., "Corticotropin-releasing factor antagonists, binding-protein and receptors: implications for central nervous system disorders," <i>Baillier's Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 13(4), 541-554
	<b>16</b>	Hoffman, J.M., "Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors," <i>J. Med. Chem.</i> , <b>1993</b> , 36, 953-966
	<b>17</b>	Huynh, C., et al., "Copper-catalysed reactions of grignard reagents with epoxides and oxetane," <i>Tetrahedron Letters</i> , <b>1979</b> , 17, 1503-1506
	<b>18</b>	Koob, G.F., et al., "Neurobiology of addiction toward the development of new therapies," <i>Ann. N.Y. Acad. Sci.</i> , <b>2000</b> , 909, 170-185
	<b>19</b>	Maillot, C., et al., "Peripheral corticotrophin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats," <i>Gastroenterology</i> , <b>2000</b> , 119, 1569-1579
	<b>20</b>	Mastorakos, G., et al., "Maternal hypothalamic-pituitary-adrenal axis in pregnancy and the postpartum period," <i>Ann. N.Y. Acad. Sci.</i> , <b>2000</b> , 900, 95-106

**EXAMINER**

**DATE CONSIDERED**

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.




<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2364/ PH-7407NP		Application No. 10/670,519	
	Applicant Thais Motria Sielecki-Dzurdz			
	Filing Date September 26, 2003		Group Not Yet Assigned	
	Confirmation No. Not Yet Assigned			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	21	McCarthy, J.R., et al., "Recent advances with the CRF <sub>1</sub> receptor: design of small molecule inhibitors, receptor subtypes and clinical indications," <i>Current Pharmaceutical Design</i> , 1999, 5, 289-315
*	22	Medicinal Chemistry: Principles and Practice, F.D. King (Ed.), <i>The Royal Society of Chemistry, Cambridge, UK, 1994</i>
	23	Misslin, R., et al., "Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents," <i>Behav. Process</i> , 1989, 18, 119-132
	24	Negishi, E., et al., "Selective carbon-carbon bond formation via transition metal catalysis.3. A highly selective synthesis of unsymmetrical biaryls and diarylmethanes by the nickel-or-palladium-catalyzed reaction of aryl-and benzylzinc derivatives with aryl halides," <i>J. Org. Chem.</i> , 1977, 42(10), 1821-1823
	25	Newport, D.J., et al., "Neurobiology of posttraumatic stress disorder," <i>Curr. Opin. In Neurobiology</i> , 2000, 10, 211-218
	26	Owens, M.J., et al., "Corticotropin-releasing factor antagonists in affective disorders," <i>Exp. Opin. Invest. Drugs</i> , 1999, 8(11), 1849-1858
	27	Pellow, S., et al., "Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat," <i>J. Neurosci. Methods</i> , 1985, 14, 149-167
	28	Porsolt, D.R., et al., "Depression: a new animal model sensitive to antidepressant treatments," <i>Nature</i> , April 21, 1997, 266, 730-732
*	29	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., <i>Mack Publishing Company, Easton, PA, 1985</i>
	30	Sato, M., et al., "Cross-coupling reaction of alkyl- or arylboronic acid esters with organic halides induced by thallium(I) salts and palladium-catalyst," <i>Chem. Letters</i> , 1989, 1405-1408

**EXAMINER**
**DATE CONSIDERED**

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2364/ PH-7407NP	Application No. 10/670,519
		Applicant Thais Motria Sielecki-Dzurdz	
		Filing Date September 26, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	31	Speicher, A., et al., "Syntheses of chlorinated bisbibenzyls from bryophytes," <i>Synthesis</i> , <b>2002</b> , 17, 2503-2512	
	32	Tomczuk, B.E., et al., "2-pheyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics," <i>J. med. Chem.</i> , <b>1991</b> , 34, 2993-3006	
	33	Vogel, J.R., et al., "A simple and reliable conflict procedure for testing anti-anxiety agents," <i>Psychopharmacologia (Berl.)</i> , <b>1971</b> , 21, 1-7	
	34	Webster, E.L., et al., "Corticotropin-releasing hormone and inflammation," <i>Ann. N.Y. Acad. Sci.</i> , <b>1998</b> , 840, 21	
	35	Willner, P., et al., "An animal model of anhedonia," <i>Clin. Neuropharmacol.</i> , <b>1992</b> , 15(Supple. 1), 550A-551A	
	36	Wynn, P.C., et al., "Regulation of corticotrophin-releasing factor (CRF) receptors in the rat pituitary gland: effects of adrenalectomy on CRF receptors and corticotroph responses," <i>The Endocrinology Soc.</i> , <b>1985</b> , 116(4), 1653-1659	
EXAMINER		DATE CONSIDERED	





<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2364/ PH-7407NP	Application No. 10/670,519
	Applicant Thais Motria Sielecki-Dzurdz	
	Filing Date September 26, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	37	5,236,901	08/17/93	Burks, et al.	514	21

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	38	WO 99/01454	01/14/99	PCT		
	39	WO 01/19825	03/22/01	PCT		
	40	WO 01/62758	08/30/01	PCT		
	41	WO 02/19975	03/14/02	PCT	X abstract	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------